IVIG for MuSK Myasthenia Gravis
For MuSK-positive myasthenia gravis with severe symptoms (Grade 3-4: dysphagia, facial weakness, respiratory muscle weakness, or rapidly progressive symptoms), administer IVIG at 2 g/kg divided over 5 days (0.4 g/kg/day), combined with corticosteroids and consider rituximab if refractory.
When to Use IVIG in MuSK-MG
Severity-Based Approach
Mild to Moderate Disease (Grade 2):
- Start with pyridostigmine (30 mg PO three times daily, titrate to max 120 mg four times daily) and corticosteroids (prednisone 0.5-1 mg/kg/day orally) 1
- Critical caveat: Cholinesterase inhibitors like pyridostigmine should be avoided in many MuSK-MG patients due to risk of clinical worsening and cholinergic crisis 2
- IVIG is not typically first-line at this stage
Severe Disease (Grade 3-4):
- Initiate IVIG immediately when patients have:
- Requires ICU-level monitoring capability
- Permanent discontinuation of immune checkpoint inhibitors if applicable
Recommended IVIG Dosing Schedule
Standard Regimen
Total dose: 2 g/kg divided over 5 days (0.4 g/kg/day) 1, 3
Infusion protocol 4:
- Initial rate: 0.01 mL/kg/min (0.5 mg/kg/min)
- If tolerated after 30 minutes, gradually increase to maximum 0.10 mL/kg/min (5 mg/kg/min)
- Monitor vital signs throughout infusion
Alternative Dosing
- 1-2 g/kg over 2 consecutive days (1 g/kg each day) for severe cases 5
- Some evidence suggests low-dose IVIG (~1.0 g/kg cumulative) may provide comparable short-term improvement to standard 2 g/kg dosing, though this requires cautious interpretation 6
Combination Therapy Approach
Concurrent treatments with IVIG:
Corticosteroids: Continue methylprednisolone 2-4 mg/kg/day or prednisone 1-1.5 mg/kg/day 1, 3
- Begin steroid taper 3-4 weeks after initiation
Plasmapheresis alternative: IVIG and plasmapheresis are equally effective 1, 3
- Do not administer plasmapheresis immediately after IVIG as it will remove the immunoglobulin 1
Rituximab for refractory cases: Add if no response to IVIG or plasmapheresis 1
- Rituximab is particularly effective in MuSK-MG and increasingly used early in disease course 2
Clinical Evidence Specific to MuSK-MG
The evidence for IVIG in MuSK-MG comes primarily from case reports showing:
- Clinical improvement observed 3 days after starting IVIG 7
- Effect duration: 2-3 months per course 7
- Potential for long-term effect exceeding 20 months in some patients 8
- Effective when conventional treatments (thymectomy, steroids, tacrolimus) have failed 7
Monitoring Requirements
During acute treatment:
- Frequent pulmonary function assessment (vital capacity, negative inspiratory force) 1, 3
- Daily neurologic review 1
- Monitor for thrombosis risk (especially in elderly, immobilized, or hypercoagulable patients) 4
- Assess renal function in at-risk patients 4
Pre-infusion screening:
- Check serum IgA levels (IgA deficiency increases anaphylaxis risk) 5
- Use IgA-reduced preparations if deficiency detected
Important Caveats for MuSK-MG
Avoid medications that worsen myasthenia: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, macrolides 1, 3
MuSK-MG differs from AChR-positive MG:
IVIG may be monophasic: Additional corticosteroid-sparing agents may not be required after successful IVIG treatment 3
Maintenance therapy: If repeated courses needed, consider monthly IVIG (1-2 g/kg) for 1-6 months 5
Risk Mitigation
For patients at high risk (elderly, renal insufficiency, thrombosis risk):